Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer

Abstract Background Chemoresistance is one of the main problems in treatment cancer. Periostin (PN) a stromal protein which mostly secreted from cancer associated fibroblasts tumor microenvironment and can promote progression including cell survival, metastasis, chemoresistance. The objective this study was to develop an anti-PN peptide bacteriophage library overcome PN effects breast (BCA) cells. Methods A twelve amino acids display used for biopanning against active site. selected clone sequenced analyzed primary structure. synthesized tested binding affinity PN. proliferation, migration drug sensitivity test were performed using overexpression BCA cells or inhibited by peptide. An intracellular signaling mechanism inhibition studied western blot analysis. Lastly, expressions patients along with clinical data. Results results showed that candidate could increase proliferation these be There significant resistance doxorubicin PN-overexpressed effect reversed associations phosphorylation AKT expression survivin. In patients, serum correlation tissue but there no Conclusions This finding supports expected development therapy reduce PN-induced chemoresistance BCA.